Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study
Price Regulation Limits Sector’s Ability To Absorb Cost Increases
Executive Summary
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.
You may also be interested in...
Canada’s CGPA Welcomes Move Towards National Pharmacare
A renewed commitment from Canada’s government to a universal national pharmacare program, included in the latest federal budget, has been welcomed by the country’s generics and biosimilars industry.
US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.
Micro-Dosing Gene Therapy: A Recipe For Success?
Utilizing the genetic overlap between frontotemporal dementia and amyotrophic lateral sclerosis, AviadoBio is seeking to develop gene therapies which can stop both these devastating diseases in their tracks using novel delivery techniques.